RxDoctor Payments Data

Cody Gomez, MD

Internal Medicine · Georgetown, TXNPI 1316357346

Payments from drug & device makers

$5,615in general payments, 2019–2025

Across 305 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$451
  • AstraZeneca$428
  • Pfizer$428
  • Amgen$423
  • GSK$412
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,58599%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk60$1,153
Lilly USA, LLC24$451
AstraZeneca(2 entities)23$428
Pfizer17$428
Amgen(2 entities)26$423
GSK28$412
Boehringer Ingelheim18$376
Abbott17$279
Johnson & Johnson14$231
Astellas Pharma US Inc12$216
AbbVie(2 entities)11$191
Exact Sciences8$162
Dexcom, Inc.8$133
Inspire Medical Systems, Inc.4$111
Bayer7$109
Amarin Pharma, Inc.4$89
Merck4$81
Radius Health, Inc.3$57
Novartis3$48
Sumitomo Pharma America, Inc.2$43
Esperion Therapeutics, Inc.2$39
Sanofi-aventis U.S. LLC2$30
Scynexis, Inc.1$25
Axonics, Inc.1$18
Althera Pharmaceuticals LLC1$15
Teleflex LLC1$14
Otsuka America Pharmaceutical, Inc.1$14
TMS Neurohealth Centers Inc.1$14
Idorsia Pharmaceuticals US Inc1$13
Bardy Diagnostics, Inc.1$12

How this compares

$5,615 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$152,301
Medicare patients
601
Services billed
1,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$43,998
MounjaroTirzepatide11$13,640
SynthroidLevothyroxine Sodium25$2,458
Losartan Potassium121$1,338
Levothyroxine Sodium120$1,334
Atorvastatin Calcium134$1,324
Rosuvastatin Calcium76$957
Amlodipine Besylate123$889
Albuterol Sulfate HfaAlbuterol Sulfate39$850
Metformin Hcl ErMetformin Hcl53$806
Duloxetine Hcl41$801
Gabapentin36$688
Pantoprazole Sodium61$650
Escitalopram Oxalate42$631
Celecoxib34$573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,153$43,99834 claims
Lilly USA, LLCMounjaro$451$13,64011 claims
AbbVieSynthroid$191$2,45825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →